Compare ARTL & NXAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ARTL | NXAT |
|---|---|---|
| Founded | 2011 | 2023 |
| Country | United States | Cayman Islands |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Movies/Entertainment |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4M | 1.2M |
| IPO Year | 2014 | 2023 |
| Metric | ARTL | NXAT |
|---|---|---|
| Price | $1.45 | $0.22 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 27.2K | ★ 148.6K |
| Earning Date | 11-12-2026 | 12-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.52 | $0.30 |
| 52 Week High | $179.19 | $1.23 |
| Indicator | ARTL | NXAT |
|---|---|---|
| Relative Strength Index (RSI) | 26.43 | 23.41 |
| Support Level | $0.52 | N/A |
| Resistance Level | $6.81 | $0.53 |
| Average True Range (ATR) | 0.25 | 0.07 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 0.00 | 2.18 |
Artelo Biosciences Inc is a United States-based development-stage biopharmaceutical company. It is engaged in the development of therapeutics that target lipid signaling pathways, including the endocannabinoid system, a family of receptors & neurotransmitters that form a biochemical communication network in the body. It is focused on discovering, licensing, developing, & commercializing treatments that control endocannabinoid systems. The company pursues technologies & programs that offer proprietary approaches to cannabinoid-based therapies, & those derived from the cannabis plant & synthetic cannabinoids, as well as new chemical entities & compounds. The firm's flagship program is designed to be a patent-protected cannabinoid drug combination treatment for a rare & orphan disease.
Nexus Advanced Technologies Inc pursuing strategic investments, acquisitions, and partnerships across AI infrastructure and technologies. The Company's ideas include opportunities involving data centers, AI compute and GPU infrastructure, and other technologies supporting the development and deployment of artificial intelligence. Nexus seeks to combine access to capital, strategic partnerships, and technology opportunities to build a diversified platform positioned to participate in the continued growth of world-wide AI infrastructure.